I was fortunate. I was born into a wonderful family. Each of my four siblings and I have certainly chosen individual paths, but it is amazing how interconnected we remain and how we can still rely on each other when necessary.
Recent events certainly demonstrated how vital family can be. Several weeks ago, as a result of a massive stroke, my father passed away peacefully surrounded by his wife of 60-plus years and his five children. It was during the days leading up to and following Dad’s death that I realized more than ever that family matters.
It is my belief that our professional lives also are draped in “family” matters. The reliance on one another to do our individual parts is just as strong. This demonstrates virtually every trait that a family embodies.
Joining a family-run business 20 years ago had its advantages. The sense of shared commitment to a common goal was not something that needed to be oft repeated. It was simply understood. And a keen sense of caring extended from the halls of our company to each and every client relationship.
Even though our business has been run independently by its management for nearly 11 years, many of the same philosophies and standards remain. An inherent attitude of teamwork and passion is ever present. This can also be said about our interactions with business partners, clients and industry contemporaries — it is indeed a family.
Please take time to share some of the familial characteristics that you see in your workplace. I can only imagine that the list will become quite lengthy.
Dave Wendland is VP and co-owner of Hamacher Resource Group, a retail healthcare consultancy located near Milwaukee, Wis. He directs business development, product innovation and marketing communications activities for the company and has been instrumental in positioning HRG among the industry’s foremost thought leaders. You may contact him at (414) 431-5301 or learn more at Hamacher.com.
Quick Sticks announces national distribution
DALLAS — A line of flavored powdered packets aimed at hypoglycemia sufferers has made its way to stores nationwide.
Quick Sticks, a quick-dissolve glucose supplement developed for hypoglycemia sufferers that require a easier way to treat symptoms of low blood sugar, now will be available at Walmart and Walgreens stores stores across the United States. Launched last year, the product initially was available at select Kroger and H-E-B stores, as well as Amazon.com.
"We’re very excited about making Quick Sticks available nationwide to those who face the everyday challenges of hypoglycemia," said Cole Egger, founder and President of QS Holdings, the maker of Quick Sticks. "We’ve been overwhelmed with positive feedback from our fans saying they love the product, so this is definitely a much-anticipated launch."
Available in sour apple and watermelon flavors, Quick Sticks carry a suggested retail price range from $5.24 to $6.49 per 12-count box.
Genzyme drug for Gaucher disease reduces enlarged spleen size in trial
CAMBRIDGE, Mass. — An experimental drug for treating a rare genetic disease appears effective, according to a late-stage clinical trial.
Sanofi subsidiary Genzyme said Tuesday that the drug eliglustat tartrate was effective in improving spleen size in previously untreated patients with Type 1 Gaucher disease in the phase-3 "Engage" trial. Gaucher disease is an enzyme deficiency disorder that affects fewer than 10,000 people worldwide and causes fat cells to collect around the spleen, liver and bone marrow. Patients with the disease may experience enlargement of the spleen and liver, anemia, excessive bleeding and bruising, bone disease and other symptoms.
"The efficacy and safety data from our Engage trial are consistent with what were observed in our phase-2 study, continuing to suggest that eliglustat tartrate is a potent, well-tolerated oral compound that may become a meaningful option for patients and physicians," Genzyme president and CEO David Meeker said. "The development of eliglustat tartrate has been underway for more than a decade and is the largest clinical program ever focused on Gaucher disease, demonstrating our ongoing commitment to innovation on behalf of this community."
The company has enrolled more than 370 patients for various studies of the drug. Top-line data from the second phase-3 trial, "Encore," are expected early next year.